KR100241228B1 - 개선된 항안드로겐 - Google Patents

개선된 항안드로겐 Download PDF

Info

Publication number
KR100241228B1
KR100241228B1 KR1019940704184A KR19940704184A KR100241228B1 KR 100241228 B1 KR100241228 B1 KR 100241228B1 KR 1019940704184 A KR1019940704184 A KR 1019940704184A KR 19940704184 A KR19940704184 A KR 19940704184A KR 100241228 B1 KR100241228 B1 KR 100241228B1
Authority
KR
South Korea
Prior art keywords
mixture
mmol
added
hydroxy
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940704184A
Other languages
English (en)
Korean (ko)
Inventor
라브리 페르낭
메랑 이브
엠므. 생 샹카
Original Assignee
라브리 페르낭
앙도르쉐르슈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라브리 페르낭, 앙도르쉐르슈 인코포레이티드 filed Critical 라브리 페르낭
Application granted granted Critical
Publication of KR100241228B1 publication Critical patent/KR100241228B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/0037—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0044—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
KR1019940704184A 1993-05-17 1993-05-20 개선된 항안드로겐 Expired - Fee Related KR100241228B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6061293A 1993-05-17 1993-05-17
US08/060612 1993-05-17
PCT/CA1993/000216 WO1994026767A1 (en) 1993-05-17 1993-05-20 Improved antiandrogens

Publications (1)

Publication Number Publication Date
KR100241228B1 true KR100241228B1 (ko) 2000-02-01

Family

ID=22030624

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704184A Expired - Fee Related KR100241228B1 (ko) 1993-05-17 1993-05-20 개선된 항안드로겐

Country Status (14)

Country Link
EP (1) EP0650495B1 (https=)
JP (1) JP2741286B2 (https=)
KR (1) KR100241228B1 (https=)
AT (1) ATE197458T1 (https=)
CA (1) CA2136303A1 (https=)
CZ (2) CZ285893B6 (https=)
DE (1) DE69329649D1 (https=)
FI (1) FI945458L (https=)
HU (1) HUT69408A (https=)
PL (1) PL307333A1 (https=)
RU (1) RU2141966C1 (https=)
SK (1) SK139194A3 (https=)
TW (1) TW259791B (https=)
WO (1) WO1994026767A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
TR200002784T2 (tr) 1998-03-11 2000-12-21 Endorecherche, Inc Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
MXPA04003611A (es) 2001-10-17 2004-07-30 Schering Corp Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
US7605152B2 (en) * 2002-01-15 2009-10-20 Merck & Co., Inc. 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
WO2004046111A1 (en) 2002-11-18 2004-06-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA05006485A (es) 2002-12-17 2005-08-26 Schering Corp Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno.
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids
US3875188A (en) * 1968-04-10 1975-04-01 Eugene E Galantay 17-Beta-alpha-lower alkyl allene-substituted steroids
FR2430952A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives acetyleniques de l'androst 4-ene, leur procede de preparation et leur application comme medicament
JPS5513273A (en) * 1978-07-13 1980-01-30 Kanebo Ltd Readily absorbable thiazolidine prodrug of anti- inflammatory corticosteroid and its drug composition
WO1991000732A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity

Also Published As

Publication number Publication date
FI945458A0 (fi) 1994-11-21
HUT69408A (en) 1995-09-28
FI945458A7 (fi) 1995-01-16
RU2141966C1 (ru) 1999-11-27
DE69329649D1 (de) 2000-12-14
JPH08510988A (ja) 1996-11-19
SK139194A3 (en) 1995-07-11
CZ285893B6 (cs) 1999-11-17
EP0650495B1 (en) 2000-11-08
WO1994026767A1 (en) 1994-11-24
RU94046463A (ru) 1997-02-27
TW259791B (https=) 1995-10-11
CZ282494A3 (en) 1995-12-13
CZ287991B6 (cs) 2001-03-14
PL307333A1 (en) 1995-05-15
JP2741286B2 (ja) 1998-04-15
FI945458L (fi) 1995-01-16
EP0650495A1 (en) 1995-05-03
ATE197458T1 (de) 2000-11-11
CA2136303A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
EP2147014B1 (en) 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
RU2141967C1 (ru) ИНГИБИТОРЫ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ
KR100383555B1 (ko) 성스테로이드활성억제제
KR101536701B1 (ko) 헬릭스 12 배향형 스테로이드계 약학 제품
EP0646007B1 (en) NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS
KR0142881B1 (ko) 성스테로이드 활성 억제용 에스트로겐 핵유도체
KR100241228B1 (ko) 개선된 항안드로겐
JPH04230295A (ja) テストステロンリダクターゼ阻害剤である新規な１７β−ヒドロキシベンゾイル−４−アザ−５α−アンドロスタ−１−エン−３−オン類
IE65269B1 (en) Aromatase inhibitors
JP2512439B2 (ja) 新規ステロイドおよび医薬
US6015806A (en) Antiandrogens
US6413951B2 (en) 20-fluoro-17(20)-vinyl steroids
EP1409512A1 (en) 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
CN1452628A (zh) 4－卤代17－亚甲基甾体、其制备方法以及包含该化合物的药物组合物
NZ280175A (en) Inhibiting testosterone 5alpha-reductase activity using an A ring modified 4-aza-3-oxo-cyclopentanoperhydrophenarthrene substituted in position-17beta by amino or acylamino
AU3405600A (en) Sex steroid activity inhibitors
IE73240B1 (en) Steroids and therapeutic compositions containing same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20021103

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20021103

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000